Page last updated: 2024-12-05

2,5-diphenyloxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12888
CHEMBL ID1418955
SCHEMBL ID46426
MeSH IDM0053375
PubMed CID7105
SCHEMBL ID74359
MeSH IDM0053375

Synonyms (100)

Synonym
4-27-00-07212 (beilstein handbook reference)
BB 0238407
1,3,4-oxadiazole, 2,5-diphenyl-
smr000146902
MLS000554785
2,5-diphenyl-[1,3,4]oxadiazole
IDI1_010278
725-12-2
nsc53152
1,4-oxadiazole, 2,5-diphenyl-
1,4-oxadiazole, 2-5-diphenyl-
wln: t5nn doj cr& er
2,5-diphenyloxadiazole
nsc-53152
IFLAB1_004523
AF-731/00082012
brn 0170385
nsc 53152
einecs 211-968-0
1,3,4-oxadiazole, 2-5-diphenyl-
2,5-diphenyl-1,3,4-oxadiazole
EU-0034399
D1429
STK407990
AKOS001219300
HMS1424N13
NCGC00246247-01
CCG-15407
HMS2282P06
FT-0610487
diphenyl-1,3,4-oxadiazole
CHEMBL1418955
1,3,4-oxadiazole,2,5-diphenyl-
SCHEMBL46426
12P-583S
DTXSID00222806
ppd (scintillator)
DCJKUXYSYJBBRD-UHFFFAOYSA-N
mfcd00003102
bdbm192661
2,5-diphenyl-1,3,4-oxadiazole (2a)
SR-01000396808-1
sr-01000396808
2-(2-phenyl-1-(pyridin-4-yl)ethylidene)hydrazinecarbothioamide
D89854
Z50150595
oxazole, 2,5-diphenyl-
nsc49168
nsc-49168
nsc-24856
PPO ,
2,5-diphenyloxazole ,
tritosol
oxazole,5-diphenyl-
ppo (scintillator)
wln: t5n coj br& dr
2,3-oxazole
usaf ek-6775
92-71-7
nsc24856
IFLAB1_004526
2,5-diphenyl-oxazole
IDI1_010281
einecs 202-181-3
dpo (scintillator)
ppo (scintillator) (van)
brn 0157021
2,5-diphenyl-1,3-oxazole
ppo (van)
nsc 24856
inchi=1/c15h11no/c1-3-7-12(8-4-1)14-11-16-15(17-14)13-9-5-2-6-10-13/h1-11
2,5-diphenyloxazole, suitable for liquid scintillation spectrometry
2,5-diphenyloxazole, 99%, suitable for scintillation
SR-01000633338-1
D0902
STL071303
HMS1424N16
AKOS000119984
[1,1-dimethyl-2-(1-piperidyl)ethyl] 3-methyl-4-oxo-2-phenyl-chromene-8-carboxylate hydrochloride
A844321
4-27-00-01435 (beilstein handbook reference)
2p8a647ryf ,
unii-2p8a647ryf
CCG-15083
FT-0610491
SC10127
SCHEMBL74359
DTXSID7059060
mfcd00005306
2,5-diphenyloxazole, 99.0%
Z56802427
2,5-diphenyl oxazole
Q3597992
AS-14429
2,5-diphenyloxazole,scintillationgrade
AMY23197
EN300-16870
D94698
2.5-diphenyloxazole
CS-W014734

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A genotoxic effect of 2,5-diphenyloxazole and its derivatives, a nonlinearity of their dose-response relationships and different effects depending on the substance concentration were found."( [Genotoxic and radioprotective properties of 2,5-diphenyloxazole and its derivatives on mice DNA structure in vivo].
Burlakova, EB; Dukhovich, FS; Noskov, VG; Zavarykina, TM; Zhizhina, GP,
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency11.22020.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency5.35820.007215.758889.3584AID588342
Nrf2Homo sapiens (human)Potency4.29370.09208.222223.1093AID624171; AID651593; AID651597
ATAD5 protein, partialHomo sapiens (human)Potency10.39100.004110.890331.5287AID504466; AID504467
P53Homo sapiens (human)Potency14.12540.07319.685831.6228AID504706
pyruvate kinaseLeishmania mexicana mexicanaPotency11.22020.398113.744731.6228AID1721; AID1722
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency1.58490.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
ras-related protein Rab-9AHomo sapiens (human)Potency1.41250.00022.621531.4954AID485297
VprHuman immunodeficiency virus 1Potency31.62281.584919.626463.0957AID651644
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
Endothelin receptor type BRattus norvegicus (Norway rat)Potency11.22020.562315.160931.6228AID1721
Endothelin-1 receptorRattus norvegicus (Norway rat)Potency11.22020.562315.160931.6228AID1721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1801909Proteolytic Activity Assay from Article 10.1016/j.bioorg.2016.05.003: \\2,5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L.\\2016Bioorganic chemistry, 08, Volume: 672,5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L.
AID677027Lipophilicity, log D of the compound at pH 7.42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxadiazoles in medicinal chemistry.
AID677028Aqueous solubility of the compound in HBSS buffer at pH 7.42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Oxadiazoles in medicinal chemistry.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (37.21)18.7374
1990's3 (6.98)18.2507
2000's8 (18.60)29.6817
2010's14 (32.56)24.3611
2020's2 (4.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.30 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews3 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other36 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]